Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KROS Keros Therapeutics, Inc.

Pre-Mkt 06-22 09:27:28 EDT

10.65

+0.24

+2.31%

High10.92	Low10.43	Vol400.53K
Open10.65	D1 Closing10.41	Amplitude4.71%
Mkt Cap209.99M	Tradable Cap105.21M	Total Shares19.72M
T/O4.27M	T/O Rate4.05%	Tradable Shares9.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KROS","market":"US","secType":"STK","nameCN":"Keros Therapeutics, Inc.","latestPrice":10.65,"timestamp":1781812800000,"preClose":10.41,"halted":0,"volume":400525,"delay":0,"changeRate":0.023054755043227685,"floatShares":9878800,"shares":19717533,"eps":-2.662597,"marketStatus":"Pre-Mkt","change":0.24,"latestTime":"06-22 09:27:28 EDT","open":10.65,"high":10.92,"low":10.43,"amount":4265487,"amplitude":0.04707,"askPrice":11.61,"askSize":1000,"bidPrice":10.5,"bidSize":34,"shortable":3,"etf":0,"ttmEps":-2.662597,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782135000000},"marketStatusCode":1,"adr":0,"listingDate":1586318400000,"exchange":"NASDAQ","adjPreClose":10.65,"postHourTrading":{"tag":"盘后","latestPrice":10.65,"preClose":10.65,"latestTime":"16:10 EDT","volume":4922,"amount":52420.297,"timestamp":1781813405325,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.5835684497768434,"impliedVol":1.0465,"impliedVolPercentile":0.872},"requestUrl":"/m/hq/s/KROS/wiki","defaultTab":"wiki","newsList":[{"id":"2644724313","title":"Keros Therapeutics director Jean Jacques Bienaime buys $10,190 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644724313","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644724313?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:56","pubTimestamp":1781729791,"startTime":"0","endTime":"0","summary":"Keros director Jean Jacques Bienaime bought 1,000 common shares at $10.19.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL66j4S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keros Therapeutics director Jean Jacques Bienaime buys $10,190 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643178592","title":"Keros director Charles W. Newton sells 550 shares for $5,522","url":"https://stock-news.laohu8.com/highlight/detail?id=2643178592","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643178592?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:16","pubTimestamp":1781554590,"startTime":"0","endTime":"0","summary":"Keros Therapeutics director Charles W. Newton sold 550 common shares on June 11, 2026 at USD 10.04.Directly held stake fell to 12,665 common shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL6MYZBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Keros director Charles W. Newton sells 550 shares for $5,522","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642348944","title":"Keros Therapeutics director Nima Farzan sells 2,625 shares for $28,163.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2642348944","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642348944?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:38","pubTimestamp":1780951115,"startTime":"0","endTime":"0","summary":"Keros Therapeutics director Nima Farzan sold 2,625 common shares on June 4, 2026 at a weighted average price of $10.73.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL9x8WGh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642643489","title":"Keros Therapeutics director Julius Knowles sells 2,625 shares for $28,163.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2642643489","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642643489?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:37","pubTimestamp":1780951022,"startTime":"0","endTime":"0","summary":"Keros Therapeutics director Julius Knowles sold 2,625 common shares on June 4, 2026 at USD 10.73.Directly held stake fell to 10,958 shares following the sale.He also reported indirect holdings of 150,047 shares and 102,233 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL1T5Qjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Keros Therapeutics director Julius Knowles sells 2,625 shares for $28,163.25","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641614775","title":"Keros Therapeutics director Seth Alpna disposes of 2,625 shares worth $28,140.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2641614775","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641614775?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:16","pubTimestamp":1780690588,"startTime":"0","endTime":"0","summary":"Keros Therapeutics director Alpna Seth sold 2,625 common shares on June 4, 2026 at a weighted average price of USD 10.72.Beneficial ownership fell to 9,767 shares following the sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL4dmXzj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Keros Therapeutics director Seth Alpna disposes of 2,625 shares worth $28,140.00","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640701189","title":"Keros Therapeutics holds annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640701189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640701189?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:02","pubTimestamp":1780516924,"startTime":"0","endTime":"0","summary":"Keros Therapeutics held its annual shareholder meeting on June 3, 2026.Shareholders selected Jean-Jacques Bienaimé, Charles Newton as directors, with terms running through the 2029 annual meeting.Shareholders ratified Deloitte & Touche as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDLbVwfDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964881","title":"Keros Therapeutics CEO to join Goldman Sachs Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964881","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964881?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:01","pubTimestamp":1780344094,"startTime":"0","endTime":"0","summary":"Keros Therapeutics will join the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.CEO Jasbir S. Seehra will take part in a fireside chat at 4:00 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6LF0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","LU2237443895.HKD","LU2750360641.GBP","LU0048573561.USD","LU2237443549.SGD","IE00B19Z3B42.SGD","LU2095319765.USD","IE0004086264.USD","LU1868836914.USD","LU0251131958.USD","IE00BSNM7G36.USD","LU1804176565.USD","LU2237443382.USD","LU1868837300.USD","LU2750360997.AUD","IE00B19Z3581.USD","KROS","IE0034235188.USD","IE00BN0W2T93.GBP","BK4139","LU0345770308.USD","SG9999014021.USD","LU0096364046.USD","BK4585","IE0004091025.USD","IE00BN0W2V16.EUR","LU1868837136.USD","BK4552","NDAQ","GSX","IE00BN0W2W23.USD","LU0942090050.USD","LU0106831901.USD","IE0002270589.USD","BK4550","SG9999014039.USD","LU1894683348.USD","LU0868494708.USD","LU2210149790.SGD","LU2471134952.CNY","BK4504","BK4533","BK4588","LU2237443978.SGD","LU2237443465.HKD","LU1894683264.USD","IE00BGHQF748.EUR","LU0345770993.USD","LU2471134879.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636327864","title":"Keros director Jean Jacques Bienaime acquires $10,580 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2636327864","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636327864?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:16","pubTimestamp":1779221785,"startTime":"0","endTime":"0","summary":"Keros Therapeutics director Jean Jacques Bienaime bought 1,000 common shares at a weighted average price of $10.58.Direct holdings rose to 9,450 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL9lqMMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keros director Jean Jacques Bienaime acquires $10,580 common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635077086","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635077086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635077086?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:11","pubTimestamp":1778843491,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX), Align Tech (ALGN) and Keros Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regenxbio-rgnx-align-tech-algn-and-keros-therapeutics-kros-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regenxbio-rgnx-align-tech-algn-and-keros-therapeutics-kros-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","LU2106854487.HKD","LU2023250504.SGD","BK4198","KROS","ALGN","LABU","LU1917777945.USD","BK4139","BK4137","RGNX","LU0128526141.USD","LU0029874061.USD","BK4505","LU2023250843.SGD","XLV","BK4581","BK4504","HCSG","XBI","BK4534","BK4585","LU1974910355.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742956","title":"Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Pelthos Therapeutics (PTHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742956?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:40","pubTimestamp":1778780407,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Keros Therapeutics (KROS) and Pelthos Therapeutics (PTHS). Keros ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-keros-therapeutics-kros-and-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-keros-therapeutics-kros-and-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","PTHS","LU0128526141.USD","BK4585","BK4137","HCSG","BK4588","XBI","KROS","LABU","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712681","title":"Keros Therapeutics Q1 FY26 turns to net loss of USD 23.71 million; revenue drops to USD 367,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712681","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712681?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:04","pubTimestamp":1778760283,"startTime":"0","endTime":"0","summary":"Keros Therapeutics posted a net loss of $23.7 million for the quarter ended March 31, 2026, swinging from net income of $148.5 million a year earlier.Revenue fell 99.83% to $367,000, driven by a drop in license revenue to no revenue from $195.36 million a year earlier.Research and development expense decreased 66.96% to $16.1 million, reflecting lower elritercept- and cibotercept-related spending as activities transitioned to Takeda and a terminated Phase 2 trial reduced costs.Cash and cash equivalents totaled $281.5 million at March 31, 2026, with runway projected into the first half of 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL99KKZx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629027907","title":"Keros Therapeutics announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2629027907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629027907?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:03","pubTimestamp":1776888194,"startTime":"0","endTime":"0","summary":"Keros Therapeutics schedules 2026 annual stockholder meeting in virtual format on June 3, 2026.Votes will cover election of two Class III directors: Jean-Jacques Bienaimé, Charles Newton.Meeting agenda includes advisory vote on compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL1MxCVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628878109","title":"Keros director Jean Jacques Biénaimé buys $11,700 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2628878109","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628878109?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:16","pubTimestamp":1776456961,"startTime":"0","endTime":"0","summary":"Keros Therapeutics director Jean Jacques Bienaime reported a purchase of 1,000 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL3gXjCm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keros director Jean Jacques Biénaimé buys $11,700 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618975458","title":"Keros Therapeutics Inc Files Initial Beneficial Ownership Statement for Director Charles W. Newton","url":"https://stock-news.laohu8.com/highlight/detail?id=2618975458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618975458?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:38","pubTimestamp":1773261512,"startTime":"0","endTime":"0","summary":"Keros Therapeutics, Inc. filed an initial statement of beneficial ownership naming Charles W. Newton as a director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL9lh623:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618697546","title":"Keros Therapeutics Director Jean Jacques Bienaime Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618697546","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618697546?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:37","pubTimestamp":1773261454,"startTime":"0","endTime":"0","summary":"Jean Jacques BIENAIME, a director of Keros Therapeutics, Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbtDG7b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keros Therapeutics Director Jean Jacques Bienaime Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618896133","title":"Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2618896133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618896133?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:35","pubTimestamp":1773174924,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Nicholas Lorusso has maintained their neutral stance on KROS stock, giving a Hold rating yesterday. Nicholas Lorusso has given his...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-hold-on-keros-as-rinvatercept-progress-offsets-execution-and-timeline-risks-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-hold-on-keros-as-rinvatercept-progress-offsets-execution-and-timeline-risks-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KROS","BK4097","LU2065732104.USD","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618931934","title":"Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618931934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618931934?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:41","pubTimestamp":1773139278,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), HeartFl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-keros-therapeutics-kros-heartflow-inc-htfl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-keros-therapeutics-kros-heartflow-inc-htfl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","LU0128526141.USD","XBI","LU0029874061.USD","HTFL","KROS","BK4588","BK4139","XLV","BK4581","HCSG","BK4585","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618629125","title":"Keros Therapeutics, Massachusetts Hospital Partner to Design Trial for Potential Lou Gehrig's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629125","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618629125?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:10","pubTimestamp":1773061831,"startTime":"0","endTime":"0","summary":"Keros Therapeutics  said Monday that it has agreed to a deal with Massachusetts General Hospital for the design of a phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis.The collaboration is part of an initiative to speed up development of new therapies for the illness using genetic and biofluid markers, the company said.Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that leads to muscle weakness and loss of physical control.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","LENZ","KROS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625790","title":"Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625790","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625790?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:17","pubTimestamp":1773058668,"startTime":"0","endTime":"0","summary":"Keros Therapeutics (KROS) announced that it has entered into an agreement with the Massachusetts General Hospital, MGH, for the design of a Phase 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-announces-collaboration-with-sean-m-healey-amg-center-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-announces-collaboration-with-sean-m-healey-amg-center-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","KROS","BK4135","IE00BGHQF748.EUR","LENZ","LU2468319806.SGD","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","AMG","LU2089984988.USD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625787","title":"Keros Therapeutics presents additional data from Phase 1 of rinvatercept","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625787?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:17","pubTimestamp":1773058645,"startTime":"0","endTime":"0","summary":"Keros Therapeutics (KROS) announced that it presented additional data from its Phase 1 clinical trial of rinvatercept in healthy volunteers at the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-presents-additional-data-from-phase-1-of-rinvatercept-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-presents-additional-data-from-phase-1-of-rinvatercept-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007","KROS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kerostx.com","stockEarnings":[{"period":"1week","weight":0.0597},{"period":"1month","weight":0.0747},{"period":"3month","weight":-0.0283},{"period":"6month","weight":-0.4743},{"period":"1year","weight":-0.214},{"period":"ytd","weight":-0.4769}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.031142},{"month":2,"riseRate":0.5,"avgChangeRate":0.032973},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.094409},{"month":4,"riseRate":0.5,"avgChangeRate":0.040837},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.080014},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.056327},{"month":7,"riseRate":0.666667,"avgChangeRate":0.015981},{"month":8,"riseRate":0.5,"avgChangeRate":0.081534},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03143},{"month":10,"riseRate":0.5,"avgChangeRate":0.115174},{"month":11,"riseRate":0.666667,"avgChangeRate":0.148933},{"month":12,"riseRate":0.5,"avgChangeRate":-0.050903}],"exchange":"NASDAQ","name":"Keros Therapeutics, Inc.","nameEN":"Keros Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Keros Therapeutics, Inc.(KROS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Keros Therapeutics, Inc.,KROS,Keros Therapeutics, Inc.股票,Keros Therapeutics, Inc.股票老虎,Keros Therapeutics, Inc.股票老虎国际,Keros Therapeutics, Inc.行情,Keros Therapeutics, Inc.股票行情,Keros Therapeutics, Inc.股价,Keros Therapeutics, Inc.股市,Keros Therapeutics, Inc.股票价格,Keros Therapeutics, Inc.股票交易,Keros Therapeutics, Inc.股票购买,Keros Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Keros Therapeutics, Inc.(KROS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction